Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2

Stock Information for Serina Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Serina Therapeutics Inc.

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.